The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome

Launched by NATIONAL CHENG-KUNG UNIVERSITY HOSPITAL · Jun 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of dextrose injections on patients with myofascial pain syndrome, particularly focusing on a condition called myofascial trigger point pain in the upper trapezius muscle (located in the neck and upper back). Participants will be divided into three groups: one group will receive a saltwater solution (normal saline), while the other two groups will receive different concentrations of dextrose (a type of sugar) to see how these injections help reduce pain and improve muscle function over time.

To be eligible for this trial, participants must be at least 20 years old, able to communicate clearly, and have been experiencing myofascial pain for more than three weeks with a specific tender point in their upper back. However, individuals with serious medical issues, certain bleeding disorders, or specific health conditions like diabetes or pregnancy cannot participate. Throughout the study, participants can expect to receive their assigned injection and then be monitored for changes in their pain and muscle condition at various points: one hour, one week, two weeks, and one month after the injection. This research aims to better understand how different types of dextrose injections might help alleviate myofascial pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1). Patients should be 20 years of age or older;
• • 2). They are able to communicate freely;
• * 3). Patients have the diagnosis of myofascial pain syndrome (MPS) with a definite myofascial trigger point (MTrP) in the neck base and upper back regions (the upper trapezius muscle). The MTrP is identified based on the following criteria, as recommended by Simons \[Simons et al., 1999\]:
• • (a). a localized tender spot in a palpable taut band of muscle fibers,
• • (b). recognized pain (as the usual clinical complaint) when the tender spot is compressed,
• • (c). characteristic and consistent referred pain.
• • 4). Symptoms of MPS should be more than 3 weeks.
• Exclusion Criteria:
• • (1). acute or serious medical problems;
• • (2). cognitive impairment or psychiatric disorder;
• • (3). coagulopathy or any other bleeding disorder;
• • (4). taking medication of anticoagulation or antithrombolytics;
• • (5). sensory deficiency over the body part where MTrPs located;
• • (6). serum hepatitis B or acquired immunodeficiency syndrome;
• • (7). malignancy;
• • (8). pregnant or likely to be pregnant.
• • (9). diabetes mellitus